Side Effects of Myeloma Treatment: Register Now for the Myeloma Crowd Round Table Interactive Webcast on December 19
Side Effects of Myeloma Treatment: Register Now for the Myeloma Crowd Round Table Interactive Webcast on December 19 image
Dec 19, 2020 / 12:00PM - 02:00PM EST
HealthTree Round Tables for Multiple Myeloma Chapter

Event Description

Understanding, Managing and Minimizing Side Effects of Treatment Sometimes the side effects of various myeloma treatments—chemotherapy, bone-strengthening drugs, monoclonal antibodies, transplant—can be as bad or worse than the disease itself. With the ever-growing range of treatment options, both minor and major side effects are part of the promise of potentially going into remission. The good news is that physicians and nurses have the tools and experience to anticipate, avoid and treat these side effects. Side effect mitigation is as important to patient care as every other part of treatment. The Myeloma Crowd Round Table Interactive Webcast on Saturday, December 19 will feature two myeloma experts who will discuss strategies and tips to help recognize and avoid adverse reactions to various treatments and procedures: Craig Hofmeister, MD, MPH, Winship Cancer Institute, Emory University, Atlanta, GA Suzanne Lentzsch, MD, PhD, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY The 90 minute program will begin at 12:00 pm Eastern Standard Time (9 am Pacific, 10 am Mountain, 11 am Central, 17:00 GMT, 18:00 CET). Each faculty member will speak for 20 minutes which will be followed by a 45 minute question and answer session open to all registered viewers. Todd Foster, HealthTree Head of Product, will describe and explain a new HealthTree profile feature that will be available called Side Effects Solutions that will be available in the New Year doing the final 30 minutes of the program. If you have any questions, please contact Greg Brozeit at or call 330-990-1090.

Schedule & Agenda

Side Effects of Myeloma Treatment
Jennifer Ahlstrom
Side Effects of Myeloma Treatment
Craig Hofmeister
* Understanding and managing myeloma bone disease issues * Avoiding and treating shingles (zoster) * Treatment-related rashes and neuropathy
Side Effects of Myeloma Treatment
Suzanne Lentzsch
* Managing cytokine release syndrome (CRS) in novel therapies * Novel therapies, novel side effects * Primary infection with influenza and COVID
Side Effects of Myeloma Treatment
Full Faculty
Questions & Answers
Health Tree: Side Effects Solutions Feature
Todd Foster
Explaining a new feature to HealthTree profiles
Side Effects of Myeloma Treatment
Jennifer Ahlstrom
Closing Remarks

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Read Bio
The panelist Greg Brozeit
Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

Read Bio
The panelist Todd Foster
Todd Foster

Todd Foster is the head of Product at HealthTree, he is an IT healthcare executive who specializes in patient experience and clinical process improvements. Todd was director of Patient and Provider Experience at MD Anderson for over a decade. Prior experience includes leadership of IT development projects at Intermountain HealthCare and United HealthCare. Todd has a passion for using technology that can help patients have a better life and along the way, help to further research for a cure.

Read Bio
The panelist Suzanne Lentzsch, MD, PhD
Suzanne Lentzsch, MD, PhD

Suzanne Lentzsch, MD, PhD, is Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Service at the Columbia University Medical Center in New York. Her translational research focuses on identifying novel targets for the treatment of myeloma, myeloma bone disease, and AL amyloidosis. Dr. Lentzsch is a member of the National Cancer Institute’s Myeloma Steering Committee, the SWOG Myeloma Working Group, co-chairs the International Myeloma Society’s Career Development Committee, and serves as a grant reviewer for the Leukemia and Lymphoma Society and Stand Up 2 Cancer (SU2C) in collaboration with the American Association for Cancer Research. She will begin a four-year term in 2021 on the American Society of Hematology’s Scientific Committee on Plasma Cell Neoplasia and as Associate Editor for the Journal of Clinical Oncology. Prior to joining Columbia University, Dr. Lentzsch served as Clinical Director of the Multiple Myeloma Program at the University of Pittsburgh Cancer Institute (UPCI). She served a research fellowship to study the mechanism of action of thalidomide and its derivatives in multiple myeloma under the mentorship of Dr. Kenneth Anderson at the Dana-Farber Cancer Institute in Boston. She completed a fellowship and residency at the Humboldt University/Charité Berlin, Germany, where she earned her MD.

Read Bio
The panelist Ana Sahagun
Ana Sahagun

Ana is an Engineer and a Psychotherapist, she has experience in both fields and loves them equally. She leads the Patient Experience Team at HealthTree and she’s passionate about talking to patients and empowering them. Whenever she’s not working you’ll find her exploring the world, eating different kinds of food, hiking or skiing.

Read Bio
The panelist Craig Hofmeister
Craig Hofmeister

Craig Hofmeister, MD, MPH, is Associate Professor of the Department of Hematology and Medical Oncology at Emory University School of Medicine and the Winship Cancer Institute. His practice focuses on plasma cell cancers, including plasmacytomas, multiple myeloma, AL amyloidosis, smoldering myeloma, and monoclonal gammopathies of renal significance. Dr. Hofmeister’s research interests include relapsed myeloma, improving the efficacy of stem cell transplantation, and the development of monoclonal antibodies. He has extensive experience in developing and leading clinical trials in the upfront and relapsed myeloma settings. Dr. Hofmeister was a finalist for the first Myeloma Crowd Research Initiative grants competition for his research in CAR T cell research to target the monoclonal antibody CS 1. He also serves on the steering committee of the Multiple Myeloma Research Consortium (MMRC). Dr. Hofmeister completed his residency and fellowships in hematology/oncology and transplant at the Loyola University Medical Center in Chicago, IL. He earned his medical degree at The Ohio State University College of Medicine in Columbus, OH.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us


+1 800 709 1113


Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811